Compare Biogen Inc (BIIB) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Open Text Corporation — how do they compare? Biogen Inc trades at $209.07 (market cap $30.13B), while Open Text Corporation trades at $23.79 (market cap $5.80B). The key difference: Biogen Inc is far larger — about 5.2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.67% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | OTEX | |
|---|---|---|
Market Cap | $30.13B | $5.80B |
Sector | Health | Technology |
52-Week High | $216.63 | $39.69 |
52-Week Low | $128.93 | $20.01 |
Enterprise Value | $37.20B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Open Text Corporation (OTEX) trades at $23.62, down 4.45% in the past 24 hours, with a bullish technical signal despite bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.23 exceeding expectations. Valuation metrics appear attractive with a P/E of 9.29 and EV/EBITDA of 5.95, while profitability remains solid with a net income margin of 12.26% and ROE of 16.19%.
The outlook is positive given consistent earnings outperformance and a consensus price target of $29.33, implying 24% upside. Risks include high debt levels and competitive pressures in the software sector. Investor sentiment is mixed, with analysts showing cautious optimism amid recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
